Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2011 | 67 | 09 |

Tytuł artykułu

Wpływ kanabinoidów na kształtowanie odpowiedzi oddechowo-ciśnieniowej w modelu zwierzęcym


Warianty tytułu

Cannabinoids’ influence on cardio-respiratory response in an animal model

Języki publikacji



Cannabinoids, the active components of Cannabis sativa, and their derivatives produce a wide spectrum of physiological effects mediated by two different types of receptors: G protein coupled cannabinoid receptor CB1 and transient receptor potential vanilloid type 1 (TRPV1). The afferent vagal pathway modulates the cardio-respiratory response to cannabinoids. The present article summarizes the cardio-respiratory effects of selected cannabinoids: endogenous anandamide and a novel drug arvanil, a metabolically stable hybrid between anandamide and capsaicin. An intravenous administration of anandamide in rats induces apnoea coupled with hypotension and evokes the decrease in the tidal volume at the early phase of reinitiated breathing. The inhibition of respiration and depression of blood pressure produced by anandamide are mediated via vagal peripheral input to the respiratory center in the medulla, while the nodose ganglia are essential in the observed phenomena. Post-anandamide apnoea and hypotension are mediated by both TRPV1 and CB1 receptors but the decline of tidal volume evoked by anandamide might depend on receptors of a different type. An administration of arvanil produced an increase of tidal volume and diaphragm activity, hypertension coupled with a fall in respiratory rate. The post-arvanil rise of tidal volume was mediated by both TRPV1 and CB1 receptors. Only vanilloid receptors seemed to be involved in the increase of diaphragm activity and decrease of respiratory frequency. Hypertensive response to arvanil might depend on receptors of a different type. The respiratory effects elicited by arvanil require intact midcervical vagi. Supranodose vagotomy failed to eliminate the hypertension evoked by arvanil. This implies that post-arvanil hypertension could be co-mediated by both vagal and extravagal pathways. The mechanism of cardio-respiratory effects of cannabinoids is worth exploring on account of their anti-tumor and anti-inflammatory actions and the possible usage of cannabinoids and their derivatives as drugs.








Opis fizyczny



  • Zakład Farmakologii Doświadczalnej, Pracownia Odruchów Oddechowych Instytutu Medycyny Doświadczalnej i Klinicznej Polskiej Akademii Nauk, ul. Pawiñskiego 5, 02-106 Warszawa


  • 1.Brooks J. W., Pryce G., Bisogno T., Jaggar S. I., Hankey D. J. R., Brown P., Bridges D., Ledent C., Bifulco M., Rice A. S. C., Di Marzo V., Baker D.: Arvanil-induced inhibition of spasticity and persistent pain: evidence for therapeutic sites of action different from the vanilloid VR1 receptor and cannabinoid CB1/CB2 receptors. Eur. J. Pharmacol. 2002, 439, 83-92.
  • 2.Cabranes A., Venderova K., de Lago E., Fezza F., Sánchez A., Mestre L., Valenti M., Garcia-Merino A., Ramos J. A., Di Marzo V., Fernández-Ruiz J.: Decreased endocannabinoid levels in the brain and beneficial effects of agents activating cannabinoid and/or vanilloid receptors in a rat model of multiple sclerosis. Neurobiol. Dis. 2005, 20, 207-217.
  • 3.Caterina M. J., Schumacher M. A., Tominaga M., Rosent T. A., Levine J. D., Julius D.: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389, 816-824.
  • 4.Chou Y.-L., Scarupa M. D., Mori N. J., Canning B. J.: Differential effects of airway afferent nerve subtypes on cough and respiration in anesthetized guinea pigs. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2008, 295, R1572-R1584.
  • 5.Coleridge J. C. G., Coleridge H. M.: Afferental vagal C fibre innervation of the lungs and airways and its functional significance. Rev. Physiol. Biochem. Pharmacol. 1984, 99, 1-110.
  • 6.Cristino L., de Petrocellis L., Pryce G., Baker D., Guglielmotti V., Di Marzo V.: Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain. Neuroscience 2006, 139, 1405-1415.
  • 7.De Lago E., Gustafsson S. B., Fernández-Ruiz J., Nilsson J., Jacobsson S. O. P., Fowler C. J.: Acyl-based anandamide uptake inhibitor cause rapid toxicity to C6 glioma cells at pharmacologically relevant concentrations. J. Neurochem. 2006, 99, 677-688.
  • 8.De Lago E., Urbani P., Ramos J. A., Di Marzo V., Fernández-Ruiz J.: Arvanil, a hybrid endocannabinoid and vanilloid compound, behaves as an antihyperkinetic agent in a rat model of Huntington’s disease. Brain Res. 2005, 1050, 210-216.
  • 9.De Petrocellis L., Melck D., Bisogno T., Di Marzo V.: Endocannabinoids and fatty acid amides in cancer, inflammation and related disorders. Chem. Phys. Lipids 2000, 108, 191-209.
  • 10.Di Marzo V., Bisogno T., De Petrocellis L.: Anandamide: some like it hot. Trends Pharmacol. Sci. 2001, 22, 346-349.
  • 11.Di Marzo V., De Petrocellis L., Fezza F., Ligresti A., Bisogno T.: Anandamide receptors. Prostag. Leukotr. Ess. 2002, 66, 377-391.
  • 12.Di Marzo V., Melck D., De Petrocellis L., Bisogno T.: Cannabimimetic fatty acid derivatives in cancer and inflammation. Prostaglandins 2000, 61, 43-61.
  • 13.Doherty P. A., McCarthy L. E., Borison H. L.: Respiratory and cardiovascular depressant effects pf nabilone, Nmethyllevonantradol and △⁹-tetrahydrocannabinol in anaesthetized cats. J. Pharmacol. Exp. Ther. 1983, 227, 508-516.
  • 14.Haxiu M. A., Lunteren van E., Deal E. C., Cherniack N. S.: Effect of stimulation of pulmonary C-fiber receptors on canine respiratory muscles. J. Appl. Physiol. 1988, 65, 1087-1092.
  • 15.Holzer P.: Capsaicin as a tool for studying neuron functions, [w:] Costa M.: Sensory Nerves and Neuropeptides in Gastroenterology: from Basis Science to Clinical Perspectives. Plenum Press, New York 1991, 3-16.
  • 16.Hou M., Uddman R., Tajti J., Kanje M., Edvinsson L.: Capsaicin receptor immunoreactivity in the human trigeminal ganglion. Neurosci. Lett. 2002, 33, 223-226.
  • 17.Kaczocha M., Glaser S. T., Deutsch D. G.: Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. USA 2009, 106, 6375-6380.
  • 18.Kazula A.: Zastosowanie naturalnych kannabinoidów i endokannabinoidów w terapii. Postępy Farmakoterapii 2009, 65, 147-160.
  • 19.Konarska L., Ellert A.: Receptory kanabinoidowe, [w:] Nowak J. Z., Zawilska J.: Receptory i mechanizmy przekazywania sygnału. Wydawnictwo Naukowe PWN, Warszawa 2004.
  • 20.Kopczyńska B.: Midcervical vagotomy precludes respiratory response to novel anti-inflammatory and anti-tumour drug arvanil in rats. Eur. J. Pharmacol. 2010, 643, 101-106.
  • 21.Kopczyńska B.: Role of VR1 and CB1 receptors in modelling of cardio-respiratory response to arvanil, an endocannabinoid and vanilloid hybrid, in rats. Life Sci. 2008, 83, 85-91.
  • 22.Kopczyńska B.: The contribution of VR1 and CB1 receptors and the role of the afferent vagal pathway in modelling of cardio-respiratory effects of anandamide in rats. Life Sci. 2007, 80, 1738-1745.
  • 23.Kopczyńska B., Sulejczak D., Wełniak-Kamińska M., Gietka A., Grieb P.: Immunohistochemiczna ocena wpływu dożylnego podania anandamidu na ekspresję białek szoku cieplnego Hsp70 i Hsp25 w płucach. Porównanie metody "klasycznej" i metody opartej na wykorzystaniu kropek kwantowych. Streszcz. V Zjazdu Pol. Tow. Farmakologii Klinicznej i Terapii: "Metody molekularne w farmakologii klinicznej od teorii do zastosowań". Poznań, 19. XI. 2009, s. 28.
  • 24.Kopczyńska B., Szereda-Przestaszewska M.: Supranodose vagotomy eliminates anandamide-evoked cardiorespiratory depression in anaesthetized rats. Respir. Physiol. Neurobiol. 2006, 152, 143-151.
  • 25.Kwolek G., Zakrzeska A., Schlicker E., Göthert M., Godlewski G., Malinowska B.: Central and peripheral components of the pressor effect of anandamide in urethane-anaesthetized rats. Brit. J. Pharmacol. 2005, 145, 567-575.
  • 26.Lake K. D., Compton D. R., Varga K., Martin B. R., Kunos G.: Cannabinoid-induced hypotension and bradycardia in rats is mediated by CB1-like cannabinoid receptors. J. Pharmacol. Exp. Ther. 1997, 281, 1030-1037.
  • 27.Lin Y. S., Lee L.-Y.: Stimulation of pulmonary vagal C-fibers by anandamide in anaesthetized rats: role of vanilloid type 1 receptors. J. Physiol. 2002, 539, 947-955.
  • 28.Malinowska B., Kwolek G., Gothert M.: Anandamide and methanandamide induce both vanilloid VR1- and cannabinoid CB1 receptor-mediated changes in heart rate and blood pressure in anaesthetized rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 2001, 364, 562-569.
  • 29.Marinelli S., Di Marzo V., Florenzano F., Fezza F., Viscomi M. T., van der Stelt M., Bernardi G., Molinari M., Maccarrone M., Mercuri N. B.: N-arachidonoyldopamine tunes synaptic transmission onto dopaminergic neurons by activating both cannabinoid and vanilloid receptors. Neuropsychopharmacol. 2007, 32, 298-308.
  • 30.Melck D., Bisogno T., De Petrocellis L., Chuang H., Julius D., Bifulco M., Di Marzo V.: Unsaturated long-chain N-acyl-vanillyl-amides (N-AVAMs): vanilloid receptor ligands that inhibit anandamide-facilitated transport and bind to CB1 cannabinoid receptors. Biochem. Bioph. Res. Co. 1999, 262, 275-284.
  • 31.Mouslech Z., Valla V.: Endocannabinoid system: An overview of its potential in current medical practice. Neuro Endocrinol. Lett. 2009, 30, 153-179.
  • 32.Oddi S., Fezza F., Pasquariello N., D'Agostino A., Catanzaro G., De Simone C., Rapino C., Finazzi-Agro A., Maccarrone M.: Molecular idendification of albumin and Hsp70 as cytosolic anandamide-binding proteins. Chemistry Biology 2009, 16, 624-632.
  • 33.Pacher P., Bátkai S., Kunos G.: Haemodynamic profile and responsiveness to anandamide of TRPV1 receptor knock-out mice. J. Physiol. 2004, 558, 647-657.
  • 34.Paleček F., Sant'Ambrogio G., Sant'Ambrogio F. B., Mathew O. P.: Reflex responses to capsaicin: intravenous, aerosol and intratracheal administration. J. Appl. Physiol. 1989, 67, 1428-1437.
  • 35.Petrosino S., Di Marzo V.: FAAH and MAGL inhibitors: therapeutic opportunities from regulating endocannabinoid levels. Curr. Opin. Investig. Drugs 2010, 11, 51-62.
  • 36.Ross R. A., Gibson T. M., Brockie H. C., Leslie M., Pashmi G., Craib S. J., Di Marzo V., Perwee R. G.: Structure-activity relationship for the endogenous cannabinoid, anandamide, and certain of its analogues at vanilloid receptors in transfected cells and vas deferens. Brit. J. Pharmacol. 2001, 132, 631-640.
  • 37.Schmid K., Niederhoffer N., Szabo B.: Analysis of the respiratory effects of cannabinoids in rats. Naunyn-Schmiedeberg's Arch. Pharmacol. 2003, 368, 301-308.
  • 38.Sharkey K. A., Cristino L., Oland L. D., Van Sickle M. D., Starowicz K., Pittman Q. J., Guglielmotti V., Davison J. S., Di Marzo V.: Arvanil, anandamide and Narachidonoyl- dopamine (NADA) inhibit emesis through cannabinoid CB1 and vanilloid TRPV1 receptors in the ferret. Eur. J. Neurosci. 2007, 25, 2773-2782.
  • 39.Smith P. J. W., McQueen D. S.: Anandamide induces cardiovascular and respiratory reflexes via vasosensory nerves in the anaesthetized rat. Br. J. Pharmacol. 2001, 134, 655-663.
  • 40.Stengel P. W., Cockerham S. L., Silbaugh S. A.: Inhaled anandamide reduces leukotriene D4- induced airway obstruction in guinea pig. Eur. J. Pharmacol. 2007, 557, 66-68.
  • 41.Sun Y., Bennett A.: Cannabinoids: A new group of agonists of PPARs. PPAR Res. 2007, 2007, 23513.
  • 42.Szallasi A., Nillsson S., Forkas-Szallasi T., Blumberg P. M., Hökfelt T., Lundberg J. M.: Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment. Brain Res. 1995, 703, 175-183.
  • 43.Szereda-Przestaszewska M., Wypych B.: Laryngeal constriction produced by capsaicin in the cat. J. Physiol. Pharmacol. 1996, 47, 351-360.
  • 44.Varga K., Lake K., Martin B. R., Kunos G.: Novel antagonist implicates the CB1 cannabinoid receptor in the hypotensive action of anandamide. Eur. J. Pharmacol. 1995, 278, 279-283.
  • 45.Veldhuis W. B., van der Stelt M., Wadman M. W., van Zadelhoff G., Maccarrone M., Fezza F., Veldink G. A., Vliegenthart J. F., Bär P. R., Nicolay K., Di Marzo V.: Neuroprotection by the endogenous cannabinoid anandamide and arvanil against in vivo excitotoxicity in the rat: role of vanilloid receptors and lipoxygenases. J. Neurosci. 2003, 23, 4127-4133.
  • 46.Vivian J. A., Kishioka S., Butelman E. R., Broadbauer J., Lee K. O., Woods J. H.: Analgesic, respiratory and heart rate effects of cannabinoid and opioid agonists in Rhesus monkeys: antagonist effects of SR 141716A. J. Pharmacol. Exp. Ther. 1998, 286, 697-703.
  • 47.Wood J. N., Docherty R.: Chemical activators of sensory neurons. Annu. Rev. Physiol. 1997, 59, 417-482.
  • 48.Yoshihara S., Morimoto H., Ohori M., Yamada Y., Abe T., Arisaka O.: Endogenous cannabinoid receptor agonists inhibit neurogenic inflammations in guinea pig airways. Int. Arch. Allergy Immunol. 2005, 138, 80-87.

Typ dokumentu



Identyfikator YADDA

JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.